Nouveau Logo communiqué de presse.JPG
Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates
26 sept. 2023 07h30 HE | Theratechnologies
Q3 2023 consolidated revenue of $20.9 million, adjusted EBITDA of $2.2 millionsBLA for F8 formulation of tesamorelin submitted to FDAAgreement in principle on key amendments to loan facility with...
Nouveau Logo communiqué de presse.JPG
Theratechnologies présente ses résultats financiers pour le troisième trimestre et les neuf premiers mois de l’exercice 2023 et fait le point sur ses activités commerciales
26 sept. 2023 07h30 HE | Theratechnologies
Revenus consolidés de 20,9 millions de dollars et BAIIA ajusté de 2,2 millions de dollars au troisième trimestre de 2023Dépôt d’une sBLA relative à la formulation F8 de la tésamoréline auprès de la...
Press Release Biocar
Press Release Biocartis Group NV: Agreement regarding recapitalization of operating subsidiaries by secured by secured creditors and wind down of listed holding company
26 sept. 2023 01h00 HE | Biocartis NV
PRESS RELEASE:INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST AGREEMENT REGARDING RECAPITALIZATION OF OPERATING SUBSIDIARIES BY SECURED CREDITORS AND WIND DOWN OF LISTED...
Persbericht Biocarti
Persbericht Biocartis Group NV: Overeenkomst betreffende herkapitalisatie van operationele dochteronderneming door gewaarborgde schuldeisers en liquidatie van beursgenoteerde holdingmaatschappij
26 sept. 2023 01h00 HE | Biocartis NV
PERSBERICHT: VOORKENNIS / GEREGULEERDE INFORMATIE 26 september 2023, 07:00 CEST OVEREENKOMST BETREFFENDE HERKAPITALISATIE VAN OPERATIONELE DOCHTERONDERNEMINGEN DOOR GEWAARBORGDE SCHULDEISERS EN...
Press Release Biocar
Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and provides an update on the operational reorganization and recapitalization
26 sept. 2023 01h00 HE | Biocartis NV
PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023 RESULTS AND PROVIDES AN UPDATE ON THE OPERATIONAL REORGANIZATION AND...
Persbericht Biocarti
Persbericht Biocartis Group NV: Biocartis kondigt resultaten H1 2023 aan en geeft een update over de operationele reorganisatie en herkapitalisatie
26 sept. 2023 01h00 HE | Biocartis NV
PERSBERICHT: VOORKENNIS / GEREGLEMENTEERDE INFORMATIE 26 september 2023, 07:00 CEST BIOCARTIS KONDIGT RESULTATEN H1 2023 AAN EN GEEFT EEN UPDATE OVER DE OPERATIONELE REORGANISATIE EN...
NOVARTIS logo.jpg
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
25 sept. 2023 01h17 HE | Novartis Pharma AG
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced...
AIMLogo.jpg
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
22 sept. 2023 09h05 HE | AIM ImmunoTech Inc.
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the...
Elevar Logo for Common Use.png
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
21 sept. 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)
21 sept. 2023 08h30 HE | Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at...